Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters

Database
Language
Document Type
Year range
1.
Tremor Other Hyperkinet Mov (N Y) ; 11: 7, 2021 02 10.
Article in English | MEDLINE | ID: covidwho-1094310

ABSTRACT

The novel coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2) is the cause of the COVID-19 pandemic [5]. SARS-Cov-2 demonstrates partial resemblance to SARS-CoV and MERS-CoV in phylogenetic analysis, clinical manifestations, and pathological findings [6, 7]. Reports emerging from China have described ataxia as a neurological symptom of the SARS-CoV-2 infection [5]. Opsoclonus consists of back-to-back multidirectional conjugate saccades without an inter-saccadic interval [8]. Myoclonus is defined as a sudden, brief, "shock-like", nonepileptic involuntary movement [9], which has been described as a symptom of SARS-CoV-2 infection [10]. Opsoclonus-Myoclonus-Ataxia syndrome (OMAS) associated COVID-19 infection has been reported recently [1112].


Subject(s)
COVID-19/physiopathology , Opsoclonus-Myoclonus Syndrome/physiopathology , Adult , COVID-19/complications , Clonazepam/therapeutic use , GABA Agents/therapeutic use , Humans , Male , Methylprednisolone/therapeutic use , Neuroprotective Agents/therapeutic use , Opsoclonus-Myoclonus Syndrome/drug therapy , Opsoclonus-Myoclonus Syndrome/etiology , Prognosis , Recovery of Function , SARS-CoV-2 , Treatment Outcome , Valproic Acid/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL